Edward Craft, DO
Family Medicine · Olmsted Twp, OHNPI 1043504780
Payments from drug & device makers
Across 405 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Lilly USA, LLC$697
- GSK$608
- Pfizer$568
- Novo Nordisk$397
- plus $2K from 25 others
What the payments were for
- Food & beverage$7,363100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,488 |
| AbbVie(2 entities) | 79 | $1,284 |
| Lilly USA, LLC | 42 | $697 |
| GSK | 37 | $608 |
| Pfizer | 33 | $568 |
| Novo Nordisk | 23 | $397 |
| Johnson & Johnson | 16 | $331 |
| Merck | 15 | $225 |
| Astellas Pharma US Inc | 10 | $183 |
| Axsome Therapeutics, Inc. | 5 | $143 |
| E.r. Squibb & Sons, L.L.C. | 7 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $127 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $122 |
| Exact Sciences | 6 | $122 |
| Boehringer Ingelheim | 8 | $117 |
| Amgen | 6 | $109 |
| Novartis | 7 | $104 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $88 |
| Abbott | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $82 |
| Biohaven Pharmaceuticals, Inc. | 3 | $70 |
| Dexcom, Inc. | 3 | $66 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Amarin Pharma, Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $27 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Antares Pharma, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,363 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $34,835 |
| EliquisApixaban | 33 | $34,682 |
| OzempicSemaglutide | 20 | $31,353 |
| MounjaroTirzepatide | 22 | $24,371 |
| JardianceEmpagliflozin | 23 | $21,828 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $19,708 |
| FarxigaDapagliflozin Propanediol | 12 | $16,228 |
| JanuviaSitagliptin Phosphate | 16 | $14,822 |
| Atorvastatin Calcium | 368 | $3,818 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 91 | $3,332 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,962 |
| Pantoprazole Sodium | 163 | $2,470 |
| Celecoxib | 54 | $2,422 |
| SynthroidLevothyroxine Sodium | 52 | $2,400 |
| Levothyroxine Sodium | 231 | $2,158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $608 | $54,54353 claims |
| PfizerEliquis | $568 | $34,68233 claims |
| Novo NordiskOzempic | $397 | $31,35320 claims |
| Lilly USA, LLCMounjaro | $697 | $24,37122 claims |
| Boehringer IngelheimJardiance | $117 | $21,82823 claims |
| AstraZenecaFarxiga | $1,488 | $16,22812 claims |
| MerckJanuvia | $225 | $14,82216 claims |
| AbbVieSynthroid | $1,284 | $2,40052 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $2,158231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Olmsted Twp
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.